Journal of Clinical Oncology, Vol 10, 1165-1170, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

G Sarosy, E Kohn, DA Stone, M Rothenberg, J Jacob, DO Adamo, FP Ognibene, RE Cunnion and E Reed
Medicine Branch, National Cancer Institute, Bethesda, MD 20892.

PURPOSE: To increase the taxol dose beyond the current standard dose intensity of 175 mg/m2 per 21 days in patients with refractory ovarian cancer. PATIENTS AND METHODS: Fifteen patients who had platinum- refractory or recurrent advanced-stage ovarian cancer were treated with taxol in a phase I trial and were given granulocyte-colony stimulating factor (G-CSF). Taxol was administered at doses of 170, 200, 250, and 300 mg/m2 every 3 weeks. G-CSF was given as a daily subcutaneous injection that started 24 hours after the completion of the taxol infusion. RESULTS: Four patients required either taxol dose reduction or delay. The dose-limiting toxicity (DLT) was peripheral neuropathy, and it occurred at 300 mg/m2. This toxicity was manifested clinically as a stocking-and-glove sensory disturbance that primarily affected proprioception, and was associated with objective changes on nerve conduction studies in affected individuals. Mucositis was rarely observed. Substantial myelosuppression was observed, but was not dose- limiting. Five of 14 assessable patients experienced an objective response to therapy, with another five individuals who experienced a 30% to 45% reduction in tumor mass. CONCLUSION: Taxol can be safely administered in doses up to 250 mg/m2 with G-CSF support, which may make it possible to study taxol dose intensification.

This article has been cited by other articles:

				D. H. Moore, J. Donnelly, W. P. McGuire, L. Almadrones, D. F. Cella, T. J. Herzog, and S. E. Waggoner Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel-Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group J. Clin. Oncol., November 15, 2003; 21(22): 4207 - 4213. [Abstract] [Full Text] [PDF]

				E. C. Kohn, E. Reed, G. A. Sarosy, L. Minasian, K. S. Bauer, F. Bostick-Bruton, V. Kulpa, E. Fuse, A. Tompkins, M. Noone, et al. A Phase I Trial of Carboxyamido-triazole and Paclitaxel for Relapsed Solid Tumors: Potential Efficacy of the Combination and Demonstration of Pharmacokinetic Interaction Clin. Cancer Res., June 1, 2001; 7(6): 1600 - 1609. [Abstract] [Full Text] [PDF]

				K. Gelmon, E. Eisenhauer, C. Bryce, A. Tolcher, L. Mayer, E. Tomlinson, B. Zee, M. Blackstein, E. Tomiak, J. Yau, et al. Randomized Phase II Study of High-Dose Paclitaxel With or Without Amifostine in Patients With Metastatic Breast Cancer J. Clin. Oncol., October 1, 1999; 17(10): 3038 - 3047. [Abstract] [Full Text] [PDF]

				K. N. Bhalla, G. N. Kumar, U. K. Walle, A. M. Ibrado, T. Javed, R. K. Stuart, C. Reed, S. G. Arbuck, and T. Walle Phase I and Pharmacologic Study of a 3-Hour Infusion of Paclitaxel followed by Cisplatinum and 5-Fluorouracil in Patients with Advanced Solid Tumors Clin. Cancer Res., July 1, 1999; 5(7): 1723 - 1730. [Abstract] [Full Text] [PDF]

				V. M.M. Herben, V. R. Nannan Panday, D. J. Richel, J. H.M. Schellens, N. van der Vange, H. Rosing, F. D. Beusenberg, S. Hearn, E. Doyle, J. H. Beijnen, et al. Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer J. Clin. Oncol., March 1, 1999; 17(3): 747 - 747. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky and R. C. Donehower Paclitaxel (Taxol) N. Engl. J. Med., April 13, 1995; 332(15): 1004 - 1014. [Full Text] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., November 18, 1993; 329(21): 1550 - 1559. [Full Text]